JP2024535740A5 - - Google Patents
Info
- Publication number
- JP2024535740A5 JP2024535740A5 JP2024513936A JP2024513936A JP2024535740A5 JP 2024535740 A5 JP2024535740 A5 JP 2024535740A5 JP 2024513936 A JP2024513936 A JP 2024513936A JP 2024513936 A JP2024513936 A JP 2024513936A JP 2024535740 A5 JP2024535740 A5 JP 2024535740A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence described
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240196P | 2021-09-02 | 2021-09-02 | |
| US63/240,196 | 2021-09-02 | ||
| US202263306395P | 2022-02-03 | 2022-02-03 | |
| US63/306,395 | 2022-02-03 | ||
| PCT/US2022/042444 WO2023034560A1 (en) | 2021-09-02 | 2022-09-02 | Antigen recognizing receptors targeting cd33 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535740A JP2024535740A (ja) | 2024-10-02 |
| JP2024535740A5 true JP2024535740A5 (enExample) | 2025-09-09 |
Family
ID=85411575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513936A Pending JP2024535740A (ja) | 2021-09-02 | 2022-09-02 | Ｃｄ３３を標的とする抗原認識受容体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240197879A1 (enExample) |
| EP (1) | EP4396215A4 (enExample) |
| JP (1) | JP2024535740A (enExample) |
| AU (1) | AU2022340644A1 (enExample) |
| CA (1) | CA3228546A1 (enExample) |
| WO (1) | WO2023034560A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085721A1 (en) * | 2023-10-18 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Chimeric receptors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221902B2 (en) * | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| EP3307779A2 (en) * | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| CN118652336A (zh) * | 2016-06-08 | 2024-09-17 | 普瑞赛格恩公司 | Cd33特异性嵌合抗原受体 |
| AU2018240556B2 (en) * | 2017-03-24 | 2025-02-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD33 immunotherapy |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| WO2020219425A1 (en) * | 2019-04-25 | 2020-10-29 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias |
-
2022
- 2022-09-02 JP JP2024513936A patent/JP2024535740A/ja active Pending
- 2022-09-02 WO PCT/US2022/042444 patent/WO2023034560A1/en not_active Ceased
- 2022-09-02 AU AU2022340644A patent/AU2022340644A1/en active Pending
- 2022-09-02 EP EP22865598.1A patent/EP4396215A4/en active Pending
- 2022-09-02 CA CA3228546A patent/CA3228546A1/en active Pending
-
2024
- 2024-02-29 US US18/591,191 patent/US20240197879A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7857980B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2024500847A5 (enExample) | ||
| JP6426713B2 (ja) | Ｇｐｃ３キメラ抗原受容体蛋白質をコードする核酸及びｇｐｃ３キメラ抗原受容体蛋白質を発現するｔリンパ球 | |
| US20220249563A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| CN110114371A (zh) | 嵌合抗原受体 | |
| JP2024023228A5 (enExample) | ||
| JP7010487B2 (ja) | 抗コチニン抗体が連結したキメラ抗原受容体およびその使用 | |
| KR20150063145A (ko) | 면역치료용 조성물 및 방법 | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| JP2023512452A (ja) | Ｂｃｍａ指向性細胞免疫療法組成物および方法 | |
| JP2022528030A5 (enExample) | ||
| CN110475857B (zh) | 表达抗-可替宁嵌合抗原受体的天然杀伤细胞 | |
| JP2022513372A5 (enExample) | ||
| CN113543809A (zh) | 用于治疗癌症的免疫疗法 | |
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| JP2022548112A5 (enExample) | ||
| JP7679298B2 (ja) | 固形腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 | |
| JP2025540340A (ja) | キメラ抗原受容体 | |
| JP2024532486A5 (enExample) | ||
| JP2025513582A (ja) | Ｂｃｍａ細胞外ドメインをマーカーとする遺伝子、ポリペプチド、組換え発現ベクター、遺伝子操作された細胞及び当該遺伝子の使用 | |
| WO2022178163A2 (en) | Antibody-derived t cell activating technologies | |
| JP2021520813A5 (enExample) | ||
| EA049516B1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ В ОТНОШЕНИИ СКОНСТРУИРОВАННЫХ И НЕСКОНСТРУИРОВАННЫХ γδ T-КЛЕТОК ДЛЯ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ |